(GCIG/JGOG 3017) CCC-1 Version 2.4-25th February 2008

• Research type

  Research Study

• Full title

  Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P)Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as First Line Chemotherapy for Clear Cell Carcinoma of the Ovary

• Sponsor organisation

  Greater Glasgow Health Board

• Eudract number

  2007-007849-13

• ISRCTN Number

  0

• Clinicaltrials.gov Identifier

  0

• Research summary

  Clear cell cancer of the ovary is a rare type of ovarian cancer. There is evidence that clear cell cancers do not respond as well as other ovarian cancers to the standard therapy of Carboplatin and Paclitaxel generally given for ovarian cancer.This trial is the result of a consensus between major research groups in ovarian cancer worldwide which concluded a study to investigate better treatments for this disease was required. The purpose of the trial is to compare the effectiveness and side effects of two chemotherapy regimens (standard arm Carboplatin and Paclitaxel versus experimental arm Irinotecan and Cisplatin). The results from a smaller randomised trial conducted using the same regimens have been encouraging, which has led to the development of this trial. <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="padding-right: 9pt; padding-left: 9pt; padding-bottom: 0cm; padding-top: 0cm"> </td> </tr> </tbody></table> <table cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="padding-right: 9pt; padding-left: 9pt; padding-bottom: 0cm; padding-top: 0cm"> </td> </tr> </tbody></table>

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  08/H1010/100

• Date of REC Opinion

  30 Jan 2009

• REC opinion

  Further Information Favourable Opinion